Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A post-hoc analysis of 1,040 LVO stroke patients reveals that the prognostic value of specific brain regions varies significantly between early (0-6h) and extended (6-24h) time windows, identifying the insula, caudate, and M6 as early-windo
The Phase 2b ELAD trial investigated liraglutide’s efficacy in mild-to-moderate Alzheimer’s disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1
Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, su
The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal
A longitudinal study of 12,268 participants reveals that women are more susceptible to cognitive decline and dementia when burdened by high blood pressure and the APOE ε4 allele compared to men.
The Phase 3 DexEnceph trial found that adjunct dexamethasone is safe in adults with HSV encephalitis but does not significantly improve verbal memory scores at 26 weeks compared to aciclovir monotherapy, suggesting a need for earlier or mor
A Phase 2 trial of crenezumab in cognitively unimpaired PSEN1 mutation carriers found no significant clinical benefit over 5-8 years, suggesting that robust amyloid plaque removal may be essential for disease modification in early-stage Alz
Researchers developed EEGSurvNet, a deep survival model that analyzes routine EEG to predict seizure risk over two years. Outperforming clinical models, it achieved an AUROC of 0.80 at two months and showed high efficacy in patients without
The international NEOS2 study validates a refined clinical score using five baseline variables to accurately predict short-term immunotherapy response, one-year functional status, and three-year return to work or school in patients with ant
Recent studies highlight the critical role of virus-specific T-cells in treating progressive multifocal leukoencephalopathy. Pre-existing T-cells predict superior responses to checkpoint inhibitors, while allogeneic T-cell transfer offers a
A secondary analysis of a randomized clinical trial reveals that parent-led enhanced developmental intervention, beginning in the NICU and spanning two years, significantly improves executive function domains—including attention, inhibition
A comprehensive Swedish study reveals that long-term exposure to particulate matter and nitrogen dioxide significantly increases the risk of Motor Neuron Disease and accelerates functional decline, even in regions with relatively low pollut
Longitudinal data from the Women’s Health Study reveal that elevated Lipoprotein(a) is a potent, independent predictor of myocardial infarction and ischemic stroke over three decades, suggesting a critical need for universal screening in pr
The NEOS2 score, an updated clinical tool, accurately predicts treatment response, one-year functional status, and three-year work/school resumption in anti-NMDAR encephalitis patients, offering clinicians a robust framework for early treat
A randomized trial demonstrates that a 50-fold smaller, closed-loop vagus nerve stimulation (CLV) system is safe and significantly improves upper limb function in chronic stroke patients, with functional gains doubling during extended home-
The CRIPTOFAST trial demonstrates that ultra-early implantation of internal loop recorders significantly increases silent atrial fibrillation detection in cryptogenic stroke patients, particularly those with subtle left atrial anomalies, of
The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the
A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resis
A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potent
A secondary analysis of the AcT trial demonstrates that high-risk plaque features—such as intraluminal thrombi and carotid webs—significantly increase stroke risk even in patients with less than 50% carotid stenosis, challenging traditional
Open language-specific specialty feeds and department pages.